Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 565,155
  • Shares Outstanding, K 85,500
  • Annual Sales, $ 420 K
  • Annual Income, $ -70,790 K
  • 36-Month Beta 1.38
  • Price/Sales 1,202.46
  • Price/Cash Flow N/A
  • Price/Book 4.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.11
  • Low Estimate -0.20
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.00 +10.17%
on 01/28/19
7.85 -15.80%
on 01/16/19
-1.03 (-13.48%)
since 01/15/19
3-Month
5.19 +27.36%
on 11/21/18
7.85 -15.80%
on 01/16/19
+1.28 (+24.02%)
since 11/15/18
52-Week
5.01 +31.94%
on 04/03/18
7.85 -15.80%
on 01/16/19
+1.32 (+24.95%)
since 02/15/18

Most Recent Stories

More News
Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Leidos Holdings, Inc. (NYSE:LDOS),...

AUPH : 6.61 (+0.61%)
MDCO : 24.77 (+3.17%)
CWST : 35.03 (+2.49%)
HURN : 54.27 (+0.95%)
NOMD : 19.25 (+1.10%)
LDOS : 63.37 (+1.67%)
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis(R) in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

--42.9% of VOS subjects vs 18.4% of Restasis(R) subjects (p=.0055) demonstrated greater-than or equal to 10mm improvement in STT at Week 4

AUP.TO : 8.71 (-0.11%)
AUPH : 6.61 (+0.61%)
Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

AUPH : 6.61 (+0.61%)
Today's Research Reports on Cotinga Pharmaceuticals, Aurinia Pharmaceuticals, Resverlogix and Hamilton Thorne

NEW YORK, NY / ACCESSWIRE / January 15, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us...

HTLZF : 0.7783 (+1.85%)
AUPH : 6.61 (+0.61%)
COT.VN : 0.095 (unch)
4 Healthcare Stocks Seeing Gains On Monday (12/31/18)

CORAL GABLES, FL / ACCESSWIRE / December 31,2018 / The is complex, this much is certain, but amidst the intricacies of the industry exists companies who are determined to innovate towards creating the...

AUPH : 6.61 (+0.61%)
Thinking about buying stock in Aurinia Pharmaceuticals Inc, Eagle Bancorp, Canada Goose Holdings Inc., New Age Beverages Corp, or vTv Therapeutics Inc.?

InvestorsObserver issues critical PriceWatch Alerts for AUPH, EBMT, GOOS, NBEV, and VTVT.

NBEV : 6.52 (-1.21%)
AUPH : 6.61 (+0.61%)
EBMT : 17.50 (+0.29%)
VTVT : 2.37 (-3.27%)
GOOS : 50.11 (-2.76%)
4 Pharma Stocks Getting a Boost on Thursday (12/20/18)

CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The healthcare industry is complicated, this much is certain, but amidst the complexities exist innovative approaches to healthcare that will ultimately...

AUPH : 6.61 (+0.61%)
GNMX : 0.23 (-6.12%)
CVSI : 4.9100 (-1.01%)
PHGI.CN : 0.830 (unch)
PHGRF : 0.6316 (+1.95%)
Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37th Annual J.P....

AUP.TO : 8.71 (-0.11%)
AUPH : 6.61 (+0.61%)
JPM : 105.55 (+3.06%)
Aurinia Establishes at-the-Market Facility

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") today announced that it has entered into an Open Market Sale Agreement (the "Sale Agreement") with Jefferies...

AUPH : 6.61 (+0.61%)
Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abeona Therapeutics Inc. (NASDAQ:ABEO),...

IMMY : 5.69 (+9.63%)
CYTK : 7.90 (+3.67%)
AUPH : 6.61 (+0.61%)
LNT : 44.98 (+0.22%)
GLDD : 7.37 (+1.38%)
ABEO : 6.63 (+2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AUPH with:

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

2nd Resistance Point 6.70
1st Resistance Point 6.65
Last Price 6.61
1st Support Level 6.53
2nd Support Level 6.46

See More

52-Week High 7.85
Fibonacci 61.8% 6.77
Last Price 6.61
Fibonacci 50% 6.43
Fibonacci 38.2% 6.09
52-Week Low 5.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar